Organization Update in Lansing, Michigan
GAITHERSBURG, Md., August 26, 2024 – Emergent continues to transform operations across all of our sites to better align with the needs and demands of our customers, as part of its multi-year transformation plan. This includes implementing a more streamlined, flexible and customer-focused model to ensure the delivery of high-quality, safe and compliant products to our customers and in a manner consistent with anticipated demand.
With this in mind, Emergent will be reducing our workforce in Lansing, Michigan by fewer than 70 roles. This change will take effect today and over the coming months. While changes in customer demand requires flexibility in our workforce planning, we remain committed to Lansing as a key element of Emergent’s future, serving as a hub for our drug substance manufacturing capabilities, as well as other critical projects.
Emergent remains a long-standing partner of the U.S. government and maintaining the anthrax manufacturing capability in Lansing is aligned with current and future global preparedness efforts. We are deeply committed to supporting our colleagues and will provide support through their transition.
About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, and Instagram.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com